移植后环磷酰胺：克服造血干细胞移植的人类白细胞抗原屏障 - Suppr

Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants.

作者信息

Bacigalupo Andrea

机构信息

Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.

出版信息

Haematologica. 2022 Jun 1;107(6):1230-1231. doi: 10.3324/haematol.2022.281256.

DOI:10.3324/haematol.2022.281256

PMID:35642483

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9152978/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ead/9152978/1f039f51f859/1071230.fig1.jpg

相似文献

Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants.移植后环磷酰胺：克服造血干细胞移植的人类白细胞抗原屏障

Haematologica. 2022 Jun 1;107(6):1230-1231. doi: 10.3324/haematol.2022.281256.

Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease.移植后大剂量环磷酰胺用于预防移植物抗宿主病。

Biol Blood Marrow Transplant. 2015 Apr;21(4):604-11. doi: 10.1016/j.bbmt.2014.08.014. Epub 2014 Aug 23.

Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.移植后环磷酰胺与抗胸腺细胞球蛋白在单倍体移植中预防移植物抗宿主病的比较

Haematologica. 2017 Feb;102(2):401-410. doi: 10.3324/haematol.2016.151779. Epub 2016 Oct 6.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.接受移植后环磷酰胺治疗的HLA匹配和HLA单倍型相同移植后的可比复合终点。

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.环磷酰胺预处理 HLA 单倍体相合造血干细胞移植后早期应用可能降低细胞因子释放综合征的发生率。

Ann Hematol. 2021 May;100(5):1295-1301. doi: 10.1007/s00277-021-04439-6. Epub 2021 Feb 12.

A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.一项关于移植后环磷酰胺联合他克莫司预防 HLA 匹配的亲缘/非亲缘异基因造血干细胞移植后移植物抗宿主病的 II 期研究。

Int J Hematol. 2022 Jan;115(1):77-86. doi: 10.1007/s12185-021-03228-1. Epub 2021 Sep 29.

Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.单剂量移植后环磷酰胺预防清髓性外周血干细胞单倍型不相关供者移植后移植物抗宿主病的II期临床试验。

Am J Hematol. 2021 Oct 1;96(10):E396-E398. doi: 10.1002/ajh.26296. Epub 2021 Jul 31.

Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.移植后环磷酰胺为主的移植物抗宿主病预防和单倍体造血干细胞移植中社区呼吸道病毒感染的发生率和影响。

Br J Haematol. 2021 Jul;194(1):145-157. doi: 10.1111/bjh.17563. Epub 2021 Jun 14.

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.急性髓系白血病患者接受同胞供者、无关供者和单倍体相合供者移植后应用环磷酰胺：ALWP EBMT 的比较研究。

J Hematol Oncol. 2020 May 6;13(1):46. doi: 10.1186/s13045-020-00882-6.

Peripheral blood stem cells for T cell-replete nonmyeloablative hematopoietic transplants using post-transplant cyclophosphamide.使用移植后环磷酰胺的富含T细胞的非清髓性造血移植的外周血干细胞

Biol Blood Marrow Transplant. 2014 May;20(5):598-9. doi: 10.1016/j.bbmt.2014.03.009. Epub 2014 Mar 15.

引用本文的文献

Acute graft-versus-host disease.急性移植物抗宿主病。

Nat Rev Dis Primers. 2023 Jun 8;9(1):27. doi: 10.1038/s41572-023-00438-1.

Human Leucocyte Antigen System and Selection of Unrelated Hematopoietic Stem Cell Donors: Impact of Patient-Donor (Mis)matching and New Challenges with the Current Technologies.人类白细胞抗原系统与无关造血干细胞供体的选择：患者-供体（错）配型的影响及当前技术带来的新挑战

J Clin Med. 2023 Jan 13;12(2):646. doi: 10.3390/jcm12020646.

本文引用的文献

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders.用 HLA 单倍体相合的亲缘供者 TCRαβ/CD19 耗竭的 HSCT 治疗不同非恶性疾病的儿童。

Blood Adv. 2022 Jan 11;6(1):281-292. doi: 10.1182/bloodadvances.2021005628.

Is Post-Transplant Cyclophosphamide the New Methotrexate?移植后环磷酰胺会成为新的甲氨蝶呤吗？

J Clin Med. 2021 Aug 12;10(16):3548. doi: 10.3390/jcm10163548.

HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.与8/8全相合和不相合无关供者骨髓移植相比，人类白细胞抗原（HLA）全相合同胞供者骨髓移植治疗慢性期慢性髓性白血病的疗效比较

J Clin Oncol. 2009 Apr 1;27(10):1644-52. doi: 10.1200/JCO.2008.18.7740. Epub 2009 Feb 17.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.采用非清髓性预处理及大剂量移植后环磷酰胺的HLA单倍型相合骨髓移植治疗血液系统恶性肿瘤

Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005.

Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia.作为急性白血病治疗手段的骨髓移植中不匹配的家庭供者

Lancet. 1983 Mar 19;1(8325):612-5. doi: 10.1016/s0140-6736(83)91793-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献